Clinical trial • Phase III • Oncology|Gastroenterology
Clinical trial in Rectal cancer (proficient mismatch repair, pMMR)
Phase III trial for Rectal cancer (proficient mismatch repair, pMMR). 20 participants.
Overview
- Trial Therapeutic Area
- Oncology|Gastroenterology
- Trial Disease
- Rectal cancer (proficient mismatch repair, pMMR)
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 08-12-2025
- First CTIS Authorization Date
- 23-02-2026
Trial design
Phase III trial across 1 site in Denmark.
- Target Sample Size
- 20
Eligibility
Recruits 20 Vulnerable population not selected; trial includes adult patients only. Consent/assent handling not described..
- Vulnerable Population
- Vulnerable population not selected; trial includes adult patients only. Consent/assent handling not described.
Recruitment
- Planned Sample Size
- 20
- Recruitment Window Months
- 83
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 20
Denmark
- Earliest CTIS Part Ii Submission Date
- 12-02-2026
- Latest Decision Or Authorization Date
- 23-02-2026
- Processing Time Days
- 11
- Number Of Sites
- 1
- Number Of Participants
- 20
Sites
- Site Name
- Copenhagen University Hospital
- Department Name
- Abdominalcenter K
- Principal Investigator Name
- Henry Smith
- Principal Investigator Email
- henry.george.smith@regionh.dk
- Contact Person Name
- Henry Smith
- Contact Person Email
- henry.george.smith@regionh.dk
- Number Of Participants
- 20
Sponsor
Primary sponsor
- Full Name
- Region Hovedstaden
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Related trials
Other published trials that may interest you.
- Girentuximab (labelled with Zirconium-89) for Gastroenteropancreatic neuroendocrine neoplasms|Hepatocellular carcinoma|Biliary tract cancer
- DOSTARLIMAB for Resectable colon cancer (pMMR/MSS)
- D,L-LYSINE ACETYLSALICYLATE for Metastatic colorectal cancer|Chemo-resistant metastatic colorectal cancer
- BEVACIZUMAB for Advanced hepatocellular carcinoma|Liver transplant recipient
- Capecitabine for Gastric adenocarcinoma|Gastroesophageal junction adenocarcinoma